Protagonist Therapeutics (PTGX) Tops Q1 EPS by 207c

Protagonist Therapeutics (NASDAQ: PTGX) reported Q1 EPS of $3.26, $2.07 better than the analyst estimate of $1.19. Revenue for the quarter came in at $254.95 million versus the consensus estimate of $120 million.

For earnings history and earnings-related data on Protagonist Therapeutics (PTGX) click here.

You May Also Be Interested In

• Ennis (EBF) Reports In-Line Q1 EPS
• Qtrex Quantum executives plan to buy up to 2M shares over 12 months
• Goldman Sachs Double Upgrades Bradsaude SA (SAUD3:BZ) to Buy